Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Mod Rheumatol ; 2023 Aug 25.
Article in English | MEDLINE | ID: mdl-37624029

ABSTRACT

OBJECTIVES: To address improvements in quality of life (QOL), we analysed the relative contributions of factors to EuroQol 5 Dimensions (EQ-5D) in abatacept-treated rheumatoid arthritis (RA) patients in the ORIGAMI study. METHODS: Patients who were evaluable for disease activity through to Week 52 in the ORIGAMI study were divided into those achieving Simplified Disease Activity Index-remission/low disease activity (remission/LDA; n=178) and patients with moderate/high disease activity (MDA/HDA; n=99). We compared the changes in EQ-5D and other outcomes through to Week 52. Focusing on the remission/LDA group, the contribution of each factor to the variance of EQ-5D at baseline and Week 52 was examined using analysis of variance. RESULTS: The remission/LDA group showed greater improvements than the MDA/HDA group in EQ-5D, Japanese Health Assessment Questionnaire, visual analogue scale for pain (Pain VAS), and patient global assessment (PtGA). In the remission/LDA group, factors significantly contributing to EQ-5D were sex, C-reactive protein, and Pain VAS at baseline, and PtGA and age at Week 52. CONCLUSIONS: In RA patients who achieved remission/LDA during abatacept treatment, PtGA and age at Week 52 contribute to the variance of EQ-5D, suggesting that identification of factors associated with PtGA may be important to address improvements of QOL.

2.
Ther Adv Musculoskelet Dis ; 15: 1759720X231186874, 2023.
Article in English | MEDLINE | ID: mdl-37539016

ABSTRACT

Background: Abatacept (ABT) is known to lower infection risk than other biologics and is effective and safe in elderly patients with rheumatoid arthritis (RA). However, there were inconsistent reports on the impact of ABT on malignancies which are more common in the elderly and strongly related to prognosis. Objectives: This study aimed to evaluate the efficacy and safety of ABT in patients with RA with previous malignancy in clinical practice. Design: A multicenter, retrospective study. Methods: Patients who received ABT for RA in two hospitals in Yokohama until May 2022 were included in this study. The patients were divided into two groups according to the presence or absence of a history of malignancy (no previous malignancy: NP group, previous malignancy: PM group). The collected parameters were compared between the groups using propensity score matching. Results: In this study, 312 patients were included, of whom 73 had previous malignancies when starting ABT. The age at ABT initiation was significantly higher in the PM group, the rate of methotrexate use was significantly lower in the PM group, and the Steinbrocker stage was significantly higher in the PM group. After matching these 3 factors, 68 patients were selected from each group. No significant differences in the ABT continuation rate, and malignancy incidence were observed between the two groups after ABT initiation. In addition to these factors, when matched for smoking history, interstitial lung disease, disease duration, sex, and inflammatory status, which are known risk factors for malignancy in RA, 40 patients were selected from each group. No significant differences in the ABT continuation rate, and malignancy incidence were observed between the two groups after ABT initiation. Conclusion: In our clinical practice, ABT was as effective and safe in patients with a history of malignancy as in those without.

3.
Intern Med ; 61(15): 2377-2385, 2022 Aug 01.
Article in English | MEDLINE | ID: mdl-35022342

ABSTRACT

Disseminated nontuberculous mycobacterial infection (DNTM) is typically observed in immunocompromised hosts. Recently, it has been reported that healthy individuals with serum neutralizing autoantibodies for interferon (IFN)-γ can also develop DNTM. We herein report a case of anti-IFN-γ antibody-seropositive DNTM caused by Mycobacterium kansasii with symptoms mimicking TAFRO or POEMS syndrome, including anasarca, organomegaly, skin pigmentation, polyneuropathy, osteosclerotic change, thrombocytopenia, serum M protein, high C-reactive protein level, and reticulin fibrosis. The combination of antimicrobial chemotherapy with glucocorticoid and intravenous immunoglobulin improved his symptoms. Glucocorticoids may be an effective method of suppressing the production of anti-IFN-γ antibodies in DNTM.


Subject(s)
Castleman Disease , Mycobacterium Infections, Nontuberculous , Opportunistic Infections , Autoantibodies , Humans , Interferon-gamma , Mycobacterium Infections, Nontuberculous/diagnosis , Mycobacterium Infections, Nontuberculous/drug therapy
4.
Mod Rheumatol Case Rep ; 4(1): 84-89, 2020 01.
Article in English | MEDLINE | ID: mdl-33086977

ABSTRACT

Optic perineuritis (OPN), which is an inflammatory disorder affecting the optic nerve sheath, is one of the rare complications in granulomatosis with polyangiitis (GPA). Although several groups have reported that immunosuppressive therapies are generally effective against GPA-associated OPN, so far, there is little information as to other options for refractory cases. Here we demonstrate a case of GPA-associated OPN, which is refractory to potent immunosuppressive therapy including high-dose glucocorticoid, intravenous cyclophosphamide and rituximab therapy, and effective application of therapeutic plasma exchange. We also report here that CSF IL-6 levels may serve as a new biomarker for GPA-associated OPN.


Subject(s)
Granulomatosis with Polyangiitis/complications , Immunosuppressive Agents/administration & dosage , Optic Neuritis/etiology , Optic Neuritis/therapy , Plasma Exchange , Biomarkers , Combined Modality Therapy , Granulomatosis with Polyangiitis/cerebrospinal fluid , Humans , Interleukin-6/cerebrospinal fluid , Optic Neuritis/cerebrospinal fluid , Optic Neuritis/diagnosis , Plasma Exchange/methods , Recurrence , Treatment Outcome
5.
Mar Pollut Bull ; 69(1-2): 228-32, 2013 Apr 15.
Article in English | MEDLINE | ID: mdl-23306066

ABSTRACT

The concentrations of PCB congeners in the blubber and liver of male and female Steller sea lions (Eumetopias jubatus; SSLs) collected from the Shakotan Peninsula and the Nemuro Strait, Hokkaido, Japan in 2008 and 2010 were measured by HRGC-HRMS, in order to express the concentration profiles in SSLs at these regions. #153 predominated in both organs, followed by #138, #99 and #118. In males, #28 and #31 were concentrated particularly in the blubber, while #177 and #199 were accumulated specifically in the liver. The differences in these concentration profiles might be expressed by the differences in the organs and their functions. The concentrations of #99, #118, #138, #153, and #180 in the blubber appeared to correspond significantly with the differences between genders. The details of the surveys on PCB congeners in SSLs could clarify the differences in the residue levels of individual congeners for organs and genders.


Subject(s)
Adipose Tissue/metabolism , Liver/metabolism , Polychlorinated Biphenyls/metabolism , Sea Lions/metabolism , Water Pollutants, Chemical/metabolism , Animals , Environmental Monitoring , Female , Japan , Male
SELECTION OF CITATIONS
SEARCH DETAIL